These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 12445542)
1. Uric acid concentrations and the mechanisms of cardiovascular disease. Waring WS; Maxwell SR; Webb DJ Eur Heart J; 2002 Dec; 23(23):1888-9. PubMed ID: 12445542 [No Abstract] [Full Text] [Related]
2. [Prophylaxis and differential therapy of tumorlysis syndrome]. Krych M; Dreyling M; Kneba M; Hoelzer D; Hiddemann W; Hallek M Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1440-5. PubMed ID: 15213877 [No Abstract] [Full Text] [Related]
3. Uric acid and cardiovascular risk. Hebert LA; Rovin B N Engl J Med; 2009 Jan; 360(5):540; author reply 540-1. PubMed ID: 19186313 [No Abstract] [Full Text] [Related]
4. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cheuk DK; Chiang AK; Chan GC; Ha SY Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561 [TBL] [Abstract][Full Text] [Related]
5. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Pui CH; Relling MV; Lascombes F; Harrison PL; Struxiano A; Mondesir JM; Ribeiro RC; Sandlund JT; Rivera GK; Evans WE; Mahmoud HH Leukemia; 1997 Nov; 11(11):1813-6. PubMed ID: 9369411 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of hyperuricemias in hematology using urate oxidase and allopurinol]. Zittoun R; Dauchy F; Teillaud C; Barthélémy M; Bouchard P Ann Med Interne (Paris); 1976; 127(6-7):479-82. PubMed ID: 970811 [No Abstract] [Full Text] [Related]
7. [Letter: Use of urate oxidase and allopurinol as hypouricemic agents in hematology]. Zittoun R; Dauchy F; Teillaud C; Barthelemy M; Bouchard P Nouv Presse Med; 1976 Jan; 5(2):91. PubMed ID: 772604 [No Abstract] [Full Text] [Related]
8. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cheuk DK; Chiang AK; Chan GC; Ha SY Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770 [TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention. Gavin AR; Struthers AD Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064 [TBL] [Abstract][Full Text] [Related]
18. Allopurinol as a therapeutic option in cardiovascular disease. Okafor ON; Farrington K; Gorog DA Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655 [TBL] [Abstract][Full Text] [Related]
19. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. George J; Struthers AD Cardiovasc Ther; 2008; 26(1):59-64. PubMed ID: 18466421 [TBL] [Abstract][Full Text] [Related]
20. Use of single-dose rasburicase in an obese female. Arnold TM; Reuter JP; Delman BS; Shanholtz CB Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]